Tryp Therapeutics (CSE: TRYP) a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced today it has appointed Dr. William K. Schmidt, a noted authority in the development of pain drugs, as a Scientific Advisory Board member. Dr. Schmidt, will aid Tryp in the development of its product candidate TRP-8802 for fibromyalgia and other chronic pain conditions.
“I’m really pleased to be able to work with a company that is developing a new therapy for fibromyalgia, which is much needed”, said Dr. Schmidt. “Based on my experience with the NIH’s Opioid Crisis task force, developing safer and more effective drugs for treating chronic pain is a national priority of the highest urgency. About 30% of fibromyalgia patients use opioids because existing medications don’t deliver sufficient pain relief.”
“We are thrilled to have Bill join our Scientific Advisory Board”, stated Dr. Jim Kuo, CEO. “I have worked with him on other pain programs and can personally attest to his regulatory and clinical trial expertise.”
Dr. William K. Schmidt serves as an expert on pain medicine pharmaceutical development with pharmaceutical and biotech companies throughout North America, Europe, Asia, Latin America, and Australia. He currently sits on the Scientific or Medical Advisory Boards of 5 biotech companies. He is the Parliamentarian and a Past-President of the Eastern Pain Association. Dr. Schmidt has received many awards throughout his career including the John J. Bonica award for the development of new analgesics and for his sustained contributions to the educational efforts of the Eastern Pain Association in 2014. He is the co-editor of “Pain: Current Understanding, Emerging, Therapies, and Novel Approaches to Drug Discovery” (Marcel Dekker, 2003). He joined DuPont Pharmaceuticals (later the DuPont Merck Pharmaceutical Company) where he helped to develop nalbuphine (Nubain®), naltrexone (Trexan®, ReVia®) and the oxycodone-ibuprofen formulation used in Combunox™. He also led the clinical teams in the development of Entereg® (alvimopan) and Acelex® (polmacoxib). Dr. Schmidt continues to chair the annual Arrowhead Pain Summit (2010-2021) and the Pharmaceutical Roundtable / Innovations in Pain Research for the Eastern Pain Association (2003-2021).
Dr. Schmidt received his Ph.D. in Pharmacology from the University of California, San Francisco. Following his postdoctoral fellowship at Boston University School of Medicine.
About Tryp Therapeutics:
Tryp Therapeutics is a pharmaceutical company focused on developing compounds with known activity and/or safety profiles for the treatment of rare diseases and other diseases with high unmet medical needs. Tryp’s psilocybin-for-neuropsychiatric disorders, or PFN™, program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of certain neuropsychiatric-based disorders….
Read More:Tryp Therapeutics Appoints Dr. William K. Schmidt to Its Scientific Advisory Board –